Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol
- PMID: 32494581
- PMCID: PMC7252278
- DOI: 10.1093/ofid/ofaa150
Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol
Abstract
Cefiderocol is a novel catechol siderophore cephalosporin antibiotic developed to treat resistant gram-negative infections. We describe its successful use as rescue therapy, combined with surgical debridement, to treat a patient with osteomyelitis due to extensively drug-resistant Acinetobacter baumannii. Bacterial whole-genome sequencing identified the strain and antibiotic resistance determinants.
Keywords: Acinetobacter baumannii; antimicrobial resistance; cefiderocol; osteomyelitis.
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures
References
-
- Dobias J, Dénervaud-Tendon V, Poirel L, Nordmann P. Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant gram-negative pathogens. Eur J Clin Microbiol Infect Dis 2017; 36:2319–27. - PubMed
-
- Trecarichi EM, Quirino A, Scaglione V, et al. ; IMAGES Group Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report. J Antimicrob Chemother 2019; 74:3399–401. - PubMed
-
- US Food and Drug Administration. Highlights of Prescribing Information: Fetroja (Cefiderocol). US Food and Drug Administration; 2019.
